Australia markets closed

Almirall SA (E2Z.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
8.43+0.10 (+1.14%)
As of 08:10AM CEST. Market open.
Full screen
Previous close8.34
Open8.43
Bid8.50 x 0
Ask8.75 x 0
Day's range8.43 - 8.43
52-week range7.43 - 9.77
Volume951
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).